Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Asston PharmaceuticalsBOM:544445 -0.59%19 Net Margin % is 38.11% as of Mar. 2026, which is 151% above its 10-year median of 15.18. GuruFocus rates BOM:544445 with a GF Score™ of 19/100. The stock has 3 warning signs investors should review. Among 962 Drug Manufacturers companies, Asston Pharmaceuticals ranks better than 79.73% on this metric.
Asston Pharmaceuticals (BOM:544445) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Asston Pharmaceuticals Net Margin % Related Terms
Asston Pharmaceuticals Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Asston Pharmaceuticals's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Asston Pharmaceuticals Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Asston Pharmaceuticals's Net Margin % distribution charts can be found below:
* The bar in red indicates where Asston Pharmaceuticals's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Asston Pharmaceuticals (BOM:544445) has a Net Margin % of 38.11% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Asston Pharmaceuticals and its competitors. This is 151% above median its historical median of 15.18. Over the past decade, Asston Pharmaceuticals' Net Margin % has ranged from 1.15 to 16.16. According to the industry distribution chart, Asston Pharmaceuticals ranks #195 out of 962 companies in the Drug Manufacturers industry, placing it in the top 20.3%.
Is Asston Pharmaceuticals' Net Margin % too high?
Asston Pharmaceuticals' current Net Margin % of 38.11% is 151% above median its 10-year median of 15.18. Over the past 10 years, this metric has ranged from a low of 1.15 to a high of 16.16. The Drug Manufacturers industry median Net Margin % is 5.37. Asston Pharmaceuticals' value of 38.11% is 609.7% above this industry median. Based on the distribution chart, Asston Pharmaceuticals ranks #195 out of 962 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Asston Pharmaceuticals has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Asston Pharmaceuticals' Net Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Asston Pharmaceuticals ranks #195 out of 962 companies for Net Margin %. This places Asston Pharmaceuticals in the top 20% of its industry — outperforming the majority of peers. The industry median Net Margin % is 5.37. Asston Pharmaceuticals' value of 38.11% is 609.7% above this benchmark. Historically, Asston Pharmaceuticals' own Net Margin % has ranged from 1.15 to 16.16 over the past decade. While the company's 10-year median is 15.18 vs. the industry median of 5.37, Asston Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.37, based on 962 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Asston Pharmaceuticals's current Net Margin % of 38.11% is 609.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Asston Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Asston Pharmaceuticals's current Net Margin % is 38.11%, which is 151% above median its own 10-year median of 15.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Asston Pharmaceuticals stock overvalued right now?
Asston Pharmaceuticals (BOM:544445) has a current Net Margin % of 38.11%. The current Net Margin % is 38.11%, which is 151% above median its 10-year median of 15.18 and 609.7% above the Drug Manufacturers industry median of 5.37. Asston Pharmaceuticals' overall GF Score™ is 19/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Asston Pharmaceuticals (BOM:544445), the current Net Margin % is 38.11% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Asston Pharmaceuticals Ltd manufactures and exports pharmaceutical and nutraceutical products. The company produces a wide range of healthcare items including tablets, capsules, syrups, sachets, ointments, creams, gels, and lotions. It serves markets in West and South Africa, with expansions planned into Asian countries. Asston conducts business through export sales, contract manufacturing and loan license arrangements via merchant exporters, and domestic sales within India. Revenue is generated through the sale of branded and generic pharmaceutical formulations along with nutraceutical products. The business operations are broadly categorized into: Domestic Formulations, Export Formulations, APIs and Intermediates, and Research and Development.
19GF Score
Get the complete analysis for BOM:544445
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544445 has been successfully added to your 
